Chen et al. report findings from a phase 1 dose expansion study of the tumor microenvironment modulator VT1021 in patients with solid tumors. VT1021 is found to be safe and tolerable, with preliminary evidence of efficacy and biomarkers of response.
- Jian Jenny Chen
- Melanie Y. Vincent
- Jing Watnick
